Oral nutritional supplements in patients with cystic fibrosis: research results

Vers V. Zarubina; Зарубина Вера В.; Olga V. Vysokolova; Высоколова Ольга В.; Mariya A. Mukhina; Мухина Мария А.; Elena E. Yakushina; Якушина Елена Е.; Тatiana N. Kekeeva; Кекеева Татьяна Н.; Irina P. Vitkovskaya; Витковская Ирина П.

doi:10.17816/medjrf636590

Oral nutritional supplements in patients with cystic fibrosis: research results

作者: Zarubina V.V.¹, Vysokolova O.V.¹, Mukhina M.A.¹, Yakushina E.E.¹, Kekeeva Т.N.¹, Vitkovskaya I.P.²^,3
隶属关系:
1. Morozov Children's Municipal Clinical Hospital
2. Russian Research Institute of Health
3. The Russian National Research Medical University named after N.I. Pirogov
期: 卷 30, 编号 6 (2024)
页面: 604-615
栏目: Original Research Articles
URL: https://bakhtiniada.ru/0869-2106/article/view/292637
DOI: https://doi.org/10.17816/medjrf636590
ID: 292637

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅存取

详细
全文:
作者简介
参考
补充文件
统计

详细

BACKGROUND: The nutritional status of patients with cystic fibrosis significantly affects their survival and the function of all organs, particularly the lungs. Due to increased protein and energy needs, these patients often require high-calorie and high-protein oral nutritional supplements (ONS).

AIM: To assess the tolerability, efficacy, and safety of Fresubin Protein® powder, a protein module.

MATERIALS AND METHODS: The data of 14 patients with mixed form of cystic fibrosis and nutritional deficiencies, aged between 6 and 16 years, were analyzed. Five patients received Fresubin Protein® powder as monotherapy (Group 1), four patients received the same therapeutic food together with emulsion of medium-chain triglycerides (Group 2), and five patients received ONS balanced in protein, fat, and carbohydrates (control group). The dynamics between percentile and Z-Scores of body mass index (BMI) at the beginning and at the end of the study period (day 180±2) were used as the main efficacy parameter of the investigated food. Body fat and lean body mass were assessed by caliperometry as additional efficacy parameters.

RESULTS: All patients showed an increase in Z-Score and BMI percentile from baseline while taking Fresubin Protein® powder both as monotherapy and in combination with medium-chain triglyceride emulsion. There were no statistically significant differences from the control group (p >0.05). However, Group 1 (100% of patients) demonstrated positive changes in muscle mass gain, as evidenced by caliperometry data, which was statistically significant (p <0.05) compared with the control group (20%). In Group 2, muscle gain was observed in 75% of the patients (p >0.05).

CONCLUSION: These findings suggest that protein-enriched ONS not only increase BMI but also contribute to muscle mass gain in patients with cystic fibrosis. New therapeutic approaches are needed, such as the inclusion of high-protein ONS in the diet to prevent muscle mass loss, along with the monitoring of body composition to improve control of disease progression.

关键词

cystic fibrosis, nutritional support, oral nutritional supplements, malnutrition, whey protein

全文:

##article.viewOnOriginalSite##

MD, Cand. Sci. (Medicine), Associate Professor

俄罗斯联邦, Moscow; Moscow

参考

Union of Paediatricians of Russia, Association of Medical Geneticists, Russian Respiratory Society, Russian Transplant Society, Association of Children's Doctors of the Moscow Region. Cystic fibrosis (cystic fibrosis): clinical recommendations. In: Rubric clinical guidelines [Internet]. Ministry of Health of the Russian Federation; 2021 [cited 03 Sep 2021]. Available from: https://cr.minzdrav.gov.ru/recomend/372_2 (In Russ.)
Kondratieva EI, Kashirskaya NYu, Kapranov NI, editors. National consensus “Cystic fibrosis: definition, diagnostic criteria, therapy”. 2nd ed. Moscow: Boroges Company; 2018, 356 p. (In Russ.)
Kapranov NI, Kashirskaya NY, Kondratieva EI, editors. Cystic fibrosis. Edition 2nd, revised and supplemented. Moscow: MEDPRACTICA-M; 2021. (In Russ.)
Sherman VD, Kondratieva EI, Voronkova AY, et al. Influence of neonatal screening for cystic fibrosis by the example of patients of the Moscow region. Medical Council. 2017;(18):124–128. EDN: ZQTKQN doi: 10.21518/2079-701X-2017-18-124-128
Vitkovskaya IP, Abramov SI, Zelenova OV. Clinical and economic justification for the inclusion of new enteral mixtures in the list of specialized products therapeutic nutrition for disabled children diagnosed with cystic fibrosis. Sovremennye problemy zdravoohranenija i medicinskoj statistiki. 2023;(1):435–449. EDN: MILLZZ doi: 10.24412/2312-2935-2023-1-435-449
Turck D, Braegger CP, Colombo C, et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 2016;35:557–77. doi: 10.1016/j.clnu.2016.03.004
Li L, Somerset S. Digestive system dysfunction in cystic fibrosis: challenges for nutrition therapy. Dig Liver Dis. 2014;46:865–874. doi: 10.1016/j.dld.2014.06.011
Calella P, Valerio G, Brodlie M, et al. Cystic fibrosis, body composition and health outcomes: a systematic review. Nutrition. 2018;55-56:131–139. doi: 10.1016/j.nut.2018.03.052
Culhane S, George C, Pearo B, Spoede E. Malnutrition in cystic fibrosis: a review. Nutr Clin Pract. 2013;28(6):676–683. doi: 10.1177/0884533613507086
Engelen MP, Com G, Deutz NEP. Protein is an important but undervalued macronutrient in the nutritional care of patients with cystic fibrosis. Curr Opin Clin Nutr Metab Care. 2014;17(6):515–520. doi: 10.1097/MCO.0000000000000100
Geukers VG, Oudshoorn JH, Taminiau JA, et al. Short-term protein intake and stimulation of protein synthesis in stunted children with cystic fibrosis. Am J Clin Nutr. 2005;81(3):605–610. doi: 10.1093/ajcn/81.3.605
Stephenson AL, Mannik LA, Walsh S, et al. Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study. Am J Clin Nutr. 2013;97(4):872–877. doi: 10.3945/ajcn.112.051409
Waterlow JC. Protein-energy malnutrition, 2nd edition. London: Edward Arnold, 1992. 407 p. ISBN-10: 0340600608, ISBN-13: 978-0340600603
WHO Guideline: Updates on the management of severe acute malnutrition in infants and children. Geneva: World Health Organization; 2013.